SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
-
SciScore for 10.1101/2020.06.08.138826: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources For detection of antigen-specific T cells, 0.5 μg/ml anti-CD49d clone L25 and 0.5 μg/ml anti-CD28 clone L293 (both from BD Biosciences) were added as a source of co-stimulation, in the presence of 0.5 μm PepMix™ SARS-CoV-2 Peptide (Spike Glycoprotein) (JPT Peptide Technologies), human CMV pp65 Peptide Pool (NIH AIDS Reagent Program), or Influenza Virus Control Peptide Pool (Anaspec). anti-CD28suggested: NoneSoftware and Algorithms Sentences Resources Data export was conducted using FlowJo (BD … SciScore for 10.1101/2020.06.08.138826: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources For detection of antigen-specific T cells, 0.5 μg/ml anti-CD49d clone L25 and 0.5 μg/ml anti-CD28 clone L293 (both from BD Biosciences) were added as a source of co-stimulation, in the presence of 0.5 μm PepMix™ SARS-CoV-2 Peptide (Spike Glycoprotein) (JPT Peptide Technologies), human CMV pp65 Peptide Pool (NIH AIDS Reagent Program), or Influenza Virus Control Peptide Pool (Anaspec). anti-CD28suggested: NoneSoftware and Algorithms Sentences Resources Data export was conducted using FlowJo (BD Biosciences) and Cytobank software. FlowJosuggested: (FlowJo, RRID:SCR_008520)Cytobanksuggested: (Cytobank, RRID:SCR_014043)Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04379076 Recruiting InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymph… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 45. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-